Ligand Pharmaceuticals was ready to spin off its antibody discovery wing into a new company when special purpose acquisition company Avista Public Acquisition Corp. came knocking.
ADQ, one of the region’s largest holding companies, announced on Thursday (September 16) that it has entered into a definitive agreement to acquire Swiss-based Acino, a leading provider of high-quality pharmaceuticals focused on growth-leading markets across the Middle East, Africa, Latin America, Russia, Ukraine and the CIS Region.
The expanded facility features an additional 4,200 square feet of space to enhance its microbiology, sterility testing, and microbial ID service offerings.
INC Research investor Avista Capital Partners has offloaded shares just days after the CRO was upgraded by a number of analysts.